Findings demonstrate the need for comprehensive personalized tumor testing to deliver actionable insights and inform effective treatment plans 

San Francisco, CA – January 17, 2019 – Scientific teams from NantHealth (NASDAQ: NH) and NantOmics will present the findings of five abstracts at the American Society of Clinical Oncology’s (ASCO) Gastrointestinal Cancers Symposium this week. The results signal the importance of expanding personalized tumor testing beyond somatic genomics to include germline genomics, transcriptomics, and other important factors as an aid in assessing the most appropriate therapies for cancer patients.

Specifically, these abstracts demonstrate methods to combine biomarkers to accurately personalize treatment strategies, especially with respect to immune checkpoint therapy (ICT) regimens in GI tumors. The powerful biomarkers explored include germline and somatic variants, microsatellite instability (MSI), tumor mutational burden (TMB), immune-pathway activity, checkpoint expression levels, and intrinsic subtypes. This comprehensive approach has identified several subpopulations of GI tumors that are at risk of receiving ineffective therapy based on somatic mutation analysis alone.

NantHealth and NantOmics teamed together in an effort to further understand the connection between mutations and gastrointestinal cancer, the second leading cause of cancer deaths in the U.S. and a major health threat to patients worldwide.

“Our scientific research is at the core of efforts to advance the practice of true precision medicine, treatment tailored to the individual patient,” said Sandeep “Bobby” Reddy, MD, Chief Medical Officer, NantHealth. “These abstracts clearly indicate the importance of examining a tumor’s entire molecular blueprint, through both DNA and RNA sequencing, to provide clinicians with the most comprehensive insights on their patient’s condition.”

NantHealth and NantOmics will present the following five abstracts:

  • Clinical trial screening of CDKN2A genomic alterations in patients with Pancreatic cancer and Hepatobiliary cancers requires greater precision than somatic sequencing alone [1/18 11:30am-1:00pm & 5:30pm-6:30pm Session B Board F5 Abstract 287]
  • Comprehensive characterization of immune landscape in gastrointestinal cancers and head and neck cancers via computational deconvolution [1/19 7:00am-7:55am & 12:15pm-1:45pm Session C Board H2 Abstract 579]
  • CMS subtypes characterized by high TMB shows immunosuppressive microenvironment that implies resistance to immunotherapy [1/19 7:00am-7:55am & 12:15pm-1:45pm Session C Board J13 Abstract 610]
  • Comprehensive-omic analysis of 152 CRC patients allows greater subclassification than CMS or sidedness alone [1/19 11:30am-1:00pm & 5:30pm-6:30pm Session C Board J4 Abstract 601]
  • Genomic and immune infiltration differences between MSI and MSS GI tumors [1/19 11:30am-1:00pm & 5:30pm-6:30pm Session B Board E11 Abstract 528]

ASCO’s Gastrointestinal Cancers Symposium is a three-day specialized meeting, held from January 17 to 19, 2019 in San Francisco, designed to provide scientific and educational content for members of the gastrointestinal cancer care and research community. This meeting encompasses the latest science in cancers of the esophagus and stomach; the pancreas, small bowel, and hepatobiliary tract; and the colon, rectum, and anus.

About NantHealth
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth’s focused portfolio exemplifies its unique systems-based approach to personalized healthcare and integrates novel diagnostics with large-scale, biometric and phenotypic data to track patient outcomes and deliver precision medicine. For more information please visit www.nanthealth.com.

About NantOmics
NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular analysis capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular analysis company to pioneer an integrated approach to unearthing the genomic variants and transcriptomic changes that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and connecting drugs to DNA to RNA changes in the tumor. NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day. For more information please visit www.nantomics.com.

Media Contact
Jen Hodson
NANT
jhodson@nantworks.com

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]